Relay Therapeutics Inc Forecast, price target & analysts
Relay Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Relay Therapeutics Inc Classifications & Recommendation
Relay Therapeutics Inc Price Target
| Target Price | $28.05 |
| Price | $18.49 |
| Potential |
51.70%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Relay Therapeutics Inc 2027 .
The average Relay Therapeutics Inc target price is $28.05.
This is
51.70%
register free of charge
$33.60
81.72%
register free of charge
$20.20
9.25%
register free of charge
|
|
| A rating was issued by 20 analysts: 19 Analysts recommend Relay Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Relay Therapeutics Inc stock has an average upside potential 2027 of
51.70%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 15.36 | 11.12 |
| 53.45% | 27.59% | |
| EBITDA Margin | -1,947.79% | -3,125.41% |
| 46.87% | 60.46% | |
| Net Margin | -1,800.00% | -3,215.36% |
| 46.65% | 78.63% |
16 Analysts have issued a sales forecast Relay Therapeutics Inc 2026 . The average Relay Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Relay Therapeutics Inc EBITDA forecast 2026. The average Relay Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Relay Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Relay Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.61 | -1.64 |
| 31.78% | 1.86% | |
| P/E | negative | |
| EV/Sales | 282.41 |
16 Analysts have issued a Relay Therapeutics Inc forecast for earnings per share. The average Relay Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Relay Therapeutics Inc...
Current Relay Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 21 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jul 08 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 21 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 08 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
